KUALA LUMPUR: Malaysian Genomics Resource Centre Bhd
has announced that its wholly-owned subsidiary, MGRC Biopharma Sdn Bhd, will be utilising technologies by AntChain Technology Pte Ltd, particularly in blockchain traceability.
The genomics and pharmaceutical specialist said its unit will be collaborating with AntChain, a subsidiary of Ant Group Digital Technologies, to employ its unique traceability technologies, together with its technical expertise in data analytics and intelligent risk management.
It said MGRC Biopharma will integrate Ant Group Digital Technologies’ AntChain TaaS traceability solution, made possible through its strategic local partnerships in the healthcare sector.
Beyond this integration, both companies are keen on exploring a spectrum of digital ventures that could amplify the efficacy and reach of MGRC’s offerings.
"By intertwining blockchain traceability within our production framework, we not only bolster product authenticity but also reinforce our promise of excellence to our stakeholders.
"This alliance is a testament to our aspiration of merging state-of-the-art technology with biopharmaceutical expertise," said Malaysian Genomics executive chairman Azri Azerai.
